Navigation Links
WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
Date:11/8/2010

SHANGHAI, Nov. 8, 2010 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it had been awarded a Certificate of Good Laboratory Practice (GLP) compliance from the State Food and Drug Administration (SFDA), China's regulatory authority for pharmaceuticals, for its toxicology facility in Suzhou.  Good Laboratory Practice is a quality system concerned with the organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived, and reported.

(Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO)

The certification covers single-dose and multiple-dose toxicology studies in both rodents and non-rodents, GeneTox studies (Ames, micronucleus, and chromosome aberration), and toxicokinetic studies.  WuXi qualified for this certification as a result of SFDA review of its management, personnel, test facilities, standard operating procedures, and study operations.  Receipt of this certification is necessary in order to perform toxicology studies to be filed in Investigational New Drug (IND) applications with the SFDA.

In September, WuXi announced that the Suzhou facility had received GLP certification from the Organization for Economic Cooperation and Development.  WuXi's Suzhou facility is the only toxicology facility in China to have received certification from both the SFDA and OECD.

"This certificate from the SFDA is an important milestone in offering our clients toxicology studies that meet both domestic and international GLP quality standards for filing INDs both in China and other countries," said Dr. Ge Li, chairman and CEO of WuXi PharmaTech.  "With this award, WuXi moves a step closer to achieving its goal of offering our pharmaceutical and biotech clients a comprehensive, fully integrated platform of pharmaceutical R&D services."

About WuXi PharmaTech WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit: http://www.wuxiapptec.com . For more information, please contact:Stephanie Liu (for the media)Tel:   +86-21-5046-4362Email: pr@wuxiapptec.comRonald Aldridge (for investors)Tel:   +1-201-585-2048Email: Ron_Aldridge@wuxiapptec.com
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech Schedules Third-Quarter 2010 Earnings Conference Call
2. Professor Steven V. Ley Speaks at WuXi PharmaTech
3. WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility
4. WuXi PharmaTech Announces Second-Quarter 2010 Results
5. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
6. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
7. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
8. WuXi PharmaTech Announces First-Quarter 2010 Results
9. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
10. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
11. WuXi PharmaTech Passes EMEA Inspection of Its GMP Manufacturing and Analytical Testing Facilities in Shanghai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Feb. 21, 2017  International Isotopes Inc. (OTCQB: INIS) ... placement with certain investors for approximately $3.4 million of ... Series C Convertible Redeemable Preferred Stock (the "Series C ... annual rate of 6% and is convertible into common ... use the proceeds for operating capital, to pay off ...
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets ... Devices - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:2/21/2017)... 21, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Uterine cancer Drugs Price Analysis and Strategies ... cancer market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Uterine cancer ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... ... Philpart, senior director at PolicyLink, will be the keynote speaker at its second ... and Men of Color Framework, which develops comprehensive strategies to create and expand ...
(Date:2/21/2017)... ... February 21, 2017 , ... Support of value-based care ... the secure exchange of data across industry solutions, Fogo Data Centers announces the launch ... community. A healthy community is one in which all systems work well, work ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is ... connected care demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and ... providers have no Health Information Exchange outside of faxing. Medal’s innovative technology “meets ...
(Date:2/20/2017)... ... February 20, 2017 , ... A new digital ... are called back for additional examinations without sacrificing cancer detection, according to a ... the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use ...
(Date:2/20/2017)... ... February 20, 2017 , ... Scrubbing in for his first ... Dr. Christopher Pezzi remembers the excitement of the surgeon training him. , “He was ... to do this? Don’t tell anyone, but I would do it for free,’” Dr. ...
Breaking Medicine News(10 mins):